Allogene Therapeutics, Inc.
ALLO$614M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSOUTH SAN FRANCISCO226 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ALLO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Fludarabine
Large B-cell Lymphoma
ALLO-647
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine | Phase 2 | Large B-cell Lymphoma | - | - |
ALLO-647 | Phase 2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply